Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 30 IN PLASTIC CONTAINER versus DEXTROSE 4 IN MODIFIED LACTATED RINGER S IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 30 IN PLASTIC CONTAINER versus DEXTROSE 4 IN MODIFIED LACTATED RINGER S IN PLASTIC CONTAINER.
DEXTROSE 30% IN PLASTIC CONTAINER vs DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose (D-glucose) is a monosaccharide that serves as a substrate for cellular energy production. It is metabolized via glycolysis and the citric acid cycle to produce ATP, and it also participates in the pentose phosphate pathway for NADPH and ribose synthesis.
Dextrose provides glucose for cellular energy metabolism. Lactated Ringer's solution replaces extracellular fluid and electrolytes. Lactate is metabolized to bicarbonate in the liver, providing buffering capacity for metabolic acidosis.
Intravenous administration; dose depends on patient's metabolic needs and clinical condition. Typical adult dose: 500 mL of 30% dextrose (150 g dextrose) infused over 4-6 hours, rate not exceeding 0.5 g/kg/hour. Frequency: as needed per blood glucose monitoring.
Intravenous infusion; adult dose is 500-1000 mL per 24 hours, titrated to fluid and electrolyte needs.
None Documented
None Documented
Not applicable; dextrose is a physiologic sugar with rapid metabolism. In diabetics, impaired utilization may prolong glucose elevation (clinical context: risk of hyperglycemia).
2–4 hours (intravenous). Clinical context: reflects glucose clearance; prolonged in renal impairment.
Dextrose is completely metabolized to carbon dioxide and water; <5% excreted unchanged in urine (renal) and none via biliary/fecal routes.
Renal: >99% as glucose. Biliary/fecal: negligible (<1%).
Category C
Category C
IV Fluid
IV Fluid